The United States Supreme Court has temporarily preserved access to mifepristone, a widely used abortion pill, by delaying a decision on potential restrictions until at least Thursday. Justice Samuel Alito issued the order, which effectively blocks a federal appeals court's imposed restrictions from taking immediate effect, allowing women to continue obtaining the medication through pharmacies or by mail.
Legal Challenge and Background
This legal challenge originates from a lawsuit filed by Louisiana, seeking to roll back the Food and Drug Administration’s established rules for prescribing mifepristone. The drug has been deemed safe and effective by FDA scientists since its approval in 2000. Lower courts had previously concluded that Louisiana was likely to prevail, with a federal appeals court panel ruling that mail access and telehealth visits for mifepristone should be suspended.
Implications for Abortion Access
The dispute highlights the ongoing legal battles over abortion access in the United States following the overturning of Roe v. Wade. Medication abortions accounted for nearly two-thirds of all abortions in 2023, underscoring the significance of mifepristone availability. The Supreme Court's temporary order ensures continued access while the court considers the matter further.
